Head And Neck Cancer - Factors Linked To Higher Death Risk Among Two Year Survivors
11/23/2011
According to a study published in the November issue of the Archives of Otolaryngology - Head & Neck Surgery, one of the JAMA/Archives journals, among individuals with head and neck cancer, continued tobacco use as well as pain and poor overall quality of life seem to be linked to worse outcomes and increased mortality rate two years after being diagnosed...
Pharynx And Mouth Cancer Mortality Rates Drop, Especially Among Patients With More Education
11/23/2011
An investigation published in the November issue of the Archives of Otolaryngology - Head & Neck Surgery, one of the JAMA/Archives journals shows that mortality rates amongst U.S. individuals suffering from mouth- and pharynx cancer have decreased from 1993 to 2007, with the highest falls observed amongst men and women with at least 12 years of education. Since the early 1990s in the U.S...
FDA Approves Erwinaze To Treat A Form Of Leukemia
11/23/2011
The U.S. Food and Drug Administration approved Erwinaze (asparaginase Erwinia chrysanthemi) to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegaspargase chemotherapy drugs used to treat ALL...
Team Identifies Tumor-Specific Pathway; Finding Could Lead To New Cancer-Stopping Therapies
11/23/2011
A research team led by UT Southwestern Medical Center scientists has identified an atypical metabolic pathway unique to some tumors, possibly providing a future target for drugs that could reduce or halt the spread of cancer. Dr. Ralph DeBerardinis, senior author of the study published Nov...
Researchers Find Men Less Willing To Be Screened For Cancer
11/23/2011
Although men have higher cancer mortality rates than women, they are less willing to be screened for cancer, according to a study conducted by researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Sanoa Consulting LLC, Muscle Shoals, Ala., and the New York University College of Dentistry...
Coffee May Protect Against Endometrial Cancer
11/23/2011
Long-term coffee consumption may be associated with a reduced risk for endometrial cancer, according to a recent study in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. Edward Giovannucci, M.D., Sc.D...
'Healthy For The Holidays' 10 Tips For Cancer Survivors
11/23/2011
Surviving the holidays with one's waistline, bank account and sanity intact can be challenging for everyone, but the season affords specific pitfalls and opportunities for cancer survivors who are mindful of staying healthy throughout the season and beyond. One in 20 adults in the U.S...
Coffee Emerges As Protective Against Cancer And Other Diseases
11/23/2011
Starbucks fans around the world can rejoice that their tipple gets the thumbs up yet again. Already shown to protect against a number of diseases, a recent study in the Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, shows coffee drinkers who consume more than four cups a day have a 25% lower risk of developing Endometrial Cancer...
Inflammatory Bowel Disease Associated With Increased Skin Cancer Risk
11/23/2011
Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications , according to two new studies in Gastroenterology, the official journal of the American Gastroenterological Association. Immunosuppressants are commonly used in the treatment of IBD...
Cisplatin Binds Like Glue In Cellular RNA
11/23/2011
An anti-cancer drug used extensively in chemotherapy binds pervasively to RNA -- up to 20-fold more than it does to DNA, a surprise finding that suggests new targeting approaches might be useful, according to University of Oregon researchers. Medical researchers have long known that cisplatin, a platinum compound used to fight tumors in nearly 70 percent of all human cancers, attaches to DNA...